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Drug-Induced Pulmonary Fibrosis
by Ian Y. R. Adamson*
The lung is a primary target of cell injury in patients receiving cytotoxic drugs, and in many cases the
reaction is severe enough to produce diffuse pulmonary fibrosis. Although many different agents may
damage the lung, the patterns of cellular injury and repair are relatively constant. Using bleomycin
toxicity as an example, it has been shown that, after IV injection, the selective site of lung injury is the
vascular endothelium; this is followed by the accumulation of interstitial edema and later by necrosis of
Type I epithelial cells. In normal repair, rapid proliferation ofType II cells, followed by differentiation to
Type I, restores the epithelial surface without fibrosis. However, after bleomycin, Type II cell proliferation
is frequently followed by abnormal differentiation to a metaplastic form of epithelium. Fibroblast
proliferation accompanies this abnormal epithelial response which is relatedeitherto selective retention of
bleomycin by epithelial cells or to the toxic effects of administering more drug at the time ofType II cell
division. It is concluded that diffuse interstitial fibrosis results from prolonged disturbance ofthe normal
epithelial-mesenchymal interrelationships at the alveolar wall. Disruption of the fibroblastic control
system by extensive epithelial necrosis or by delayed or inappropriate repair may be the key factor in
instigating fibroblast proliferation and subsequent deposition of collagen. This mechanism may account
for the development ofdiffuse fibrosis or fibrosing alveolitis in response to a variety ofpulmonary toxins.
The association between the development of pulmo-
nary disease in humans and the administration of
various chemicals has been made with increasing fre-
quency in recent years. In particular, the increased
incidence of diffuse pulmonary fibrosis in patients
receiving various forms of cancer chemotherapy has
implicated the lung as a primary target for a number of
cytotoxic agents. Drug-induced lung disease is difficult
to diagnose with any degree of certainty due to the
many variables encountered in studying a human
population. Factors such as medical history, variable
immune status, possible role ofinfection and interaction
with other drugs or irradiation make it difficult to
identify the causal factor(s) in the development of
pulmonary disease.
From a series of case reports it is clear that a great
variety of chemical agents may induce rather similar
clinical signs and symptoms and, on biopsy or at
autopsy, the cellular changes seeninthe lung, atleastin
late stages, are also similar. For example, pulmonary
fibrosis was reported in 1973 as a side effect of
nitrofurantoin treatment (1,2). Radiographic evidence
ofprogressive fibrosis and interstitial pneumonitis was
confirmedbymorphologic studies. Various tests seemed
to rule out an immunologic mechanism and, though a
direct toxic reaction has been postulated, the precise
mechanism of pulmonary injury is unknown. Similarly,
diffuse pulmonary fibrosis is associated with busulphan
and melphalan therapies for leukemia and multiple
myeloma (3,4). In one case, where the patient died
after receiving only melphalan, interstitial fibrosis was
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associated with atypical alveolarhyperplasia. This asso-
ciation ofepithelial changes and underlyingfibrosis was
seen in several other melphalan patients and in other
studies of different alkylating agents such as cyclo-
phosphamide (5) and mitomycin (6). In the latter study,
histologic examination revealed alveolar septal edema
with some interstitial infiltrates and hypertrophy of
alveolar lining cells accompanied by thickening of the
septal walls with collagen. A similar pattern has been
seen in paraquat poisoning where, at biopsy, there was
severe damage to the alveolar epithelium with signs of
pulmonary fibrosis; subsequently at necropsy, this had
progressed to massive intra-alveolar and interstitial
fibrosis (7).
Many other agents have now been identified as toxic
tothe lung, and ithas been suggested that most cases of
idiopathic pulmonary fibrosis are in fact drug-induced.
Although the available evidence indicates that there is
initial damage to the air-blood barrier with fibrosis
developing as a reparative event, no clear pathogenesis
can be reconstructed from these scattered clinical
reports. In recent years, however, the drug bleomycin
has also been shown to induce similarfibrotic changes in
the lung (8) and it has proved suitable for detailed
experimental studies. In dealing with this agent in
some depth, it is believed that the cellular mechanisms
involved in its toxicity may be valid for drug-induced
lung disease in general.
PulmonaryToxicityofBleomycin
The antibiotic bleomycin has been used with increas-
ing frequency over the last 10 years in the treatment of
several types of tumors, including squamous cellI. Y R. ADAMSON
carcinomas, lymphomas and testicular tumors. The
drug was first isolated from Streptomyces verticillatus
in Japan, where it was shown to be a mixture of
glycopeptides with differences in their terminal amine
groups (9,10). Initially, the drug was found to be
effective on squamous cell carcinomas without inducing
therenaltoxicitythatwasfoundwithrelatedantibiotics,
but with increasing use, it became apparent that
bleomycin is toxic to the lung and can produce diffuse
pulmonary fibrosis accompanied by epithelial meta-
plasia.
Bleomycin has some advantages over other cytotoxic
drugs principally because it does not have major effects
on the bone marrow (9,11) or on immunocompetence
in animals or humans (12,13). In all cells, normal or
neoplastic, the drug is initially concentrated in the
cytoplasm where it is degraded by an enzyme which
cleaves carboxyamide groups (9). There is now a clear
relationship between responsiveness of a cell type to
bleomycin and low levels of the degradative enzyme
(14). Epidermal cells in general appear to contain low
levels of inactivating enzyme, so bleomycin can more
readily reach the nucleus where the ultimate damage is
fragmentation of DNA with subsequent changes in the
synthesis of DNA, RNA and protein (15). Some of the
DNA strand damage may repair, but usually the cell
cycle is affected, often leading to cell death. These
effects are therefore more readily seen in rapidly
dividing cells such as tumor cells, in particular in
tumors of epidermal cell origin with the low level of
inactivating enzyme.
The usual limiting factor in prescribing bleomycin is
the risk ofpulmonary fibrosis. This occurrence appears
to be related to total dose administered and the initial
guideline of300 mg total dose to humans has now been
reduced to 150 mg (16). Previous lung injury may also
exclude or limit the use of bleomycin in some patients,
and it has also been reported that prior radiotherapy
increases the risk of pulmonary toxicity to bleomycin
(17). Drug administration is usually stopped at the first
sign of lung damage as seen by X-rays or pulmonary
functiontests, but often the injury willprogress further
to pulmonary fibrosis (8).
Biopsies ofthese injured lungs show diffuse alveolar
damage. Figures 1-3 illustrate the pulmonary lesions
in a patient who received bleomycin treatment for an
epidermoid carcinoma of the esophagus. Although the
tumor size decreased, the lungs developed extensive
interstitial fibrosis with some areas of intra-alveolar
fibrosis (Fig. 1). In some regions ofthe lung, the alveoli
were lined by cuboidal, metaplastic epithelial cells lying
on a thickfibrous interstitium (Fig. 2). Electron micros-
copy showed a variety ofepithelial cell forms, including
tubules of undifferentiated cells reminiscent of fetal
epithelium. More common were areas of proliferated
cuboidall1pe II cells associatedwithinterstitialfibrosis
(Fig. 3).
Various animal models have now been used to study
the pulmonary toxicity of bleomycin. In experiments
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FIGURE 1. Humanlungafterbleomycintreatmentforanesophageal
tumor. Lungisconsolidated withextensive areas ofinterstitial and
intraalveolar fibrosis. H & E stain, x250.
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FIGURE 2. Human lung after bleomycin. Metaplastic cuboidal epi-
thelial cells line some alveoli and cover athick fibrous interstitium:
(A) alveolus; (V) vessel. H & E stain, x665.
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FIGURE 3. Biopsy ofhuman lungafterbleomycin. The electron micrograph shows fibrosingalveolitis with agroup ofType II cells (EP) overlying
a thickened interstitium (INT) containing many fibroblasts and collagen fibers. EM, x3000.
where dogs received various doses of bleomycin intra-
venously, Fleischman et al. (18) found varying degrees
ofepithelial reactivity with inflammatory cell infiltrates
and fibrosis as post-injection time increased. Later,
Adamson and Bowden used multiple intraperitoneal
injections ofbleomycin to mice, as a model for inducing
epithelial metaplasia and pulmonary fibrosis (19). From
dose/mortality figures, they showed that a higher dose
was needed to produce pulmonary changes in mice than
in dogs; 0.4 mg/kg produced lesions in dogs (18),
whereas mice required at least 8-10 times this dose for
significant damage to occur (19). Following the intra-
peritoneal administration of 20 mg/kg bleomycin twice
per week for 4 to 8 weeks, most animals developed
perivascular edema with cellular infiltrates, and, in
addition, a proportion ofthese mice also showed epithe-
lial metaplasia and fibrosis.
Pulmonary fibrosis in mice has also been produced
after a single large intravenous dose ofbleomycin. The
administration of 120 mg/kg bleomycin IV resulted in
50% mortality with most of the surviving animals
developing diffuse pulmonary fibrosis (20). Autopsies on
animals dying with or without lung disease showed that
other organs were normal on both gross and histologic
examination. It was concluded that the lungis a specific
target for bleomycin.
More rapid and severe interstitial pulmonary fibrosis
has been produced experimentally by instilling a single
dose of bleomycin intratracheally to rats (21) and
hamsters (22,23). In these studies morphologic evi-
dence of fibrosis was correlated with enhanced synthe-
sis ofhydroxyproline, collagen and elastin. In hamsters
the changes were also correlated with significant deteri-
oration in pulmonary function as measured by lung
compliance and capacity. The results of these studies,
together with evidence that bleomycin-induced pulmo-
nary fibrosis in baboons (24) is similar to that seen
clinically, indicate that experimental studies on the
pathogenesis andmechanismoflunginjurybybleomycin
are relevant to the human disease process. The bleo-
mycin model may also have more general application in
providing some understanding of cellular mechanisms
leading to diffuse fibrosing alveolitis induced by a
variety of toxic chemicals.
PathogenesisofPulmonaryFibrosis
Many agents, both airborne and bloodborne, are
known to damage the cells ofthe lung but the patterns
of injury and repair are relatively few. The overall
determination of lung injury and repair from measure-
ments of protein, DNA, RNA and collagen does not
take account ofthe complex cellular composition of the
lungoroftheknownheterogeneityofcellularresponses.
Following bleomycin, pulmonary cells demonstrate this
differential susceptibility to injury. The cellular events
following a large single dose of bleomycin to mice (120
mg/kg) are similar to those observed after multiple
intraperitoneal injections (20 mg/kg twice weekly),
though the time sequence is accelerated. The earliest
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changes observed by electron microscopy involved the
endothelium of pulmonary arteries and veins where
subendothelial blebs bulged into the vascular lumen,
resulting in severe attenuation of the endothelial
cytoplasm; in addition, there was intracytoplasmic
edema ofthe endothelial cells (Fig. 4). This was seen as
soon as 2 weeks after the start of the intraperitoneal
injections and 2 days after the intravenous dose.
Subsequently, these changes were detected by light
microscopy and were accompanied by accumulation of
edema fluid in perivascular spaces. Lesions of large
pulmonary vessels occurred before changes were seen
inthe capillary endothelium where the cells alsobecame
swollen and separated from the underlying basement
membrane. It is likely that this resulted in permeability
changes since evidence ofdiffuse interstitial edema was
found at that time.
The endothelium was therefore identified as the
primary site of injury and the anatomic pattern of the
lesions is likely related to the mode ofdrug administra-
tion. The preferential susceptibility of endothelial cells
ofarteries and veins can be related to the fact that the
drugis bloodborne. This is in contrast to injury induced
by oxygen or other oxidant gases where the cells on the
route of maximum gaseous transfer, the capillary
endothelium, are preferentially injured (25,26). The
circulating drug initially must reach and enter the
pulmonary endothelium to produce its cytotoxic effects,
and the particular sensitivity of this cell type to
bleomycin is probably related to a low level ofinactivat-
ing enzyme.
The endothelium has been traditionally regarded as a
waterproof, coagulation-proof lining layer with trans-
port activity. Recently this view has been modified by
metabolic studies showing that endothelial cells bear
surface enzymes and receptor sites (27). Injury to the
pulmonary endothelium usually results in the leakage of
fluid into the interstitium and, in some animals receiv-
ing the large intravenous injection of bleomycin, lung
injury did not progressbeyond endothelial swellingwith
the accumulation of interstitial edema; this was also
true for animals thatreceived only a few intraperitoneal
injections. Inbothinstances, thelesionswerereversible;
the edema disappeared, and restitution of a normal
blood-air barrier was associated with endothelial cell
division, as seen in autoradiographs of lung following
3H-thymidine injection at the time of repair (20). In
instances where there is more severe or prolonged
FIGURE 4. Pulmonary vein ofa mouse after 2 weeks bleomycin (four injections IP, 20 mg/kg). Severe cytoplasmic edema ofendothelial cells is
accompanied by subendothelial edema causing swelling of cells into the lumen: (V) vessel lumen; (E) edema; (INT) interstitium; (EN)
endothelium. EM, x 12,000. Reproduced from Adamson and Bowden (19) with permission.DRUG-INDUCED PULMONARY FIBROSIS
damage to the endothelium, for example, after irradi-
ation, the disturbance ofthe endothelial-interstitial cell
balance appears to promote fibroblast proliferation. In
such a case severe endothelial damage alone, though
repaired later, may be associated with interstitial
fibrosis.
The most critical cellular event following bleomycin
administration is destruction of the 15ype I epithelium.
This attenuated cell forms a barrier that initially limits
the edema fluid to the interstitium. Since the perme-
ability of the vascular endothelium is altered, circulat-
ing bleomycin probably has access to cells of the
interstitium and epithelium, and it appears that the
drug is toxic to alveolar epithelial cells. As noted in
other models of lung injury, there is a differential
response of the alveolar epithelium, whereby focal
necrosis of the squamous Type I cells was observed
(Fig. 5) and the cuboidal Type II cells appeared
relatively normal. By destroying this epithelial barrier,
the contents of the interstitium and of the blood may
leak through damaged endothelium directly to the
alveoli, and in fact, necrosis of TIype I cells was
frequently associated with intra-alveolar aggregates of
fibrin (19). If this is massive, the animals will die;
however, if multifocal, they survive and the lung
undergoes a reparative fibrotic reaction.
Following bleomycin, fibrosis was observed in two
distinctcompartmentsofthelung. Infibrin-filledalveoli,
fibroblasts migrated from interstitium across the de-
nuded epithelium to the alveoli where they surround the
fibrin and secrete collagen to produce areas of intra-
alveolar fibrosis (19). Fibroblastic activity was also
prominent in the pulmonary interstitium around both
capillaries and larger vessels giving a picture typical of
fibrosing alveolitis (Fig. 6). Both the septal and intra-
alveolar fibrosis became progressively more extensive
and severe with time (Fig. 7). In animals thatreceived a
20 mg/kg dose twice per week for 8 weeks, fibrosis was
first observed at 4 weeks, then progressed to become
diffuse by 4 to 12 weeks, whereas mice receiving IV
bleomcyin developed fibrosis by 2 to 4 weeks.
It can be seen that the morphology ofthe late stages
ofthe pulmonary reaction is similarin the human (Figs.
1-3) and animal (Figs. 6 and 7) studies. The formation of
intra-alveolar and interstitial fibrosis appears to follow
the same pattern after bleomycin as that described for
experimental paraquat poisoning where the key event is
also disintegration of the alveolar epithelium (28,29).
In the case ofparaquat, the alveolar damage is usually
much more severe with massive intra-alveolar edema
and/or hemorrhage resulting in death (7); the few
survivors with much less epithelial injury develop
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FIGURE 5. Mouse lung after 4 weeks bleomycin IP Swelling of capillary endothelial cells is accompanied by interstitial edema (E). In several
areas there is necrosis of 1Type I epithelium (EP1). EM, x4200.
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FIGURE 6. Mouse lung after 6 weeks IP bleomycin. Regenerating epithelium (EP) shows various cell forms varying from undifferentiated to
typical Type II cell. The air-blood barrier is now thickened by fibrosis (INT) interstitium EM x8400.
fibrosis. In this case also, migration offibroblasts to the
alveoli as well as interstitial proliferation and secretion
of collagen, resulted in consolidation of the lungs with
rapidly deteriorating pulmonary function. It may be
postulated therefore that the epithelial cell injury
destroysthecriticalepithelial-mesenchymalcontrolrela-
tionship and is at least partly responsible for the onset
of fibrosis.
Inthe case ofbleomycintoxicity, fibrosis was accompa-
nied by reactive hyperplasia and metaplasia of alveolar
epithelial cells and the amount offibrosis appeared to be
related to the severity ofthe epithelial lesions. Afterthe
period of Type I cell necrosis, evidence of reparative
activity was found in the alveolar epithelium. It is
generally accepted that the Type I epithelial cells ofthe
air-blood barrier are susceptible to injury by a variety
of bloodborne or airborne agents. Acute injury is fol-
lowed by epithelial repair, accomplished by division of
type II cells, some of which transform to the Type I
form to restore the normal air-blood barrier. This
process, which occurs after oxygen (30), nitrogen diox-
ide (31) and intraperitoneal butylated hydroxytoluene
(32), is a recapitulation of events in the fetal develop-
ment of the alveolar epithelium (33). The initial events
in bleomycin toxicity were similar, Type I cell necrosis
was followed by Type II cell division.
Mitotic figures were seen in some cuboidal Type II
cells (19); in focal areas, alveolar walls were lined
exclusively by this type ofepithelium (Fig. 6). However,
the usual process of differentiation to TIype I cells did
not always occur. Some cells probably transformed to
Type I but others seemed to undergo change to a
metaplastic form of epithelium, in which the alveolar
lining cells were cuboidal, possessed microvilli but not
lamellar bodies (19). Many alveoli were lined by these
tubular forms that resemble undifferentiated fetal epi-
thelium and are also similar to the epithelial forms seen
in the bleomycin-injured human lung (Fig. 2).
The frequency of observing metaplastic epithelial
cells in fibrotic areas of mouse lung increased with the
number ofinjections following biweekly intraperitoneal
administration at 20 mg/kg. Many giant Type II cells
were seen at 8 weeks; they were often binucleate and
disruption of nuclear structure occurred in some cells
(Fig. 8). The development of ciliated alveolar cells was
observed from 8 to 12 weeks afterthe start ofbleomycinDRUG-INDUCED PULMONARY FIBROSIS
FIGURE 7. Mouse lung after 8 weeks IP bleomycin showing massive
interstitial and intra-alveolar fibrosis. Silver methenanine stain,
x 130.
injections. This change was focal in nature and, within
any one alveolar tubule, a variety ofcellular forms was
observed including typical Type II cells, ciliated cells
without lamellar bodies and intermediate forms with
haphazard arrays of microvilli and cilia (Fig. 9). By 12
weeks, occasional foci ofsquamous metaplasia lined the
original alveoli (19) and ciliated alveolar epithelium was
readily recognized by light microscopy (Fig. 10). These
findings suggest that the Type II cells divided toinitiate
epithelial repair but that the effects of the drug on
epithelial DNA subverted the post mitotic processes of
differentiation to produce a variety of inappropriate
alveolar lining cells.
It could be argued that bronchiolar epithelial cells
had grown down into the alveoli to repair the injury but
the finding of these metaplastic forms in distal regions
ofthe lung makes it likely that they were derived from
alveolar epithelial cells. Additional evidence that the
metaplastic cells arose from altered differentiation of
the alveolar epithelium comes from a cytodynamic
study (20). After a large intravenous dose ofbleomycin,
mice were killed at various intervals, with3H-thymidine
FIGURE 8. After multiple bleomycin injections, nuclear disintegra-
tion of some Type II epithelial cells is seen. EM, x 10,000.
Reproduced from Adamson and Bowden (47) with permission.
injected 1 hr before sacrifice. From combined mor-
phologic and autoradiographic studies it was shown
that, following epithelial injury, regenerative activity
occurred promptly. After 12 days many alveoli were
lined by large cuboidal cells, a number of which had
incorporated tritiated thymidine. The overall labeling of
alveolar cells was maximal at 12 days and most of the
cells labeled at this time were proliferatingType II cells
(Fig. 11). Immediately prior to this peak, endothelial
labeling was observed, and in the period 14-28 days, as
fibrosis developed, evidence ofthymidine incorporation
was seen in fibroblasts. Labeling of bronchial and
bronchiolar epithelial cells never exceeded control val-
ues throughout the study, indicating that the metaplas-
tic epithelial cells were of alveolar origin, the result of
inappropriate differentiation after a period of division
(Fig. 11).
The standard pattern ofrepair to the alveolar wall is
rapid regeneration of surviving endothelial cells (25)
and lype II epithelial cell proliferation followed by
transformation toT3ype I (30). Whenlunginjuryis acute
and focal, these events occur rapidly and fibrosis does
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FIGURE 9. Areaofalveolarepithelium, 4weeksafteralarge IVdoseofbleomycin. Variousepithelialcellformslinethealveolus(ALV), aType II
cell with typical lamellar bodies, is bounded by two cuboidal cells with a mixture of cilia and mnicrovilli at the surface. EM, x6000.
FIGURE 10. Mouse lung 10 weeks after IP bleomycin. In some areas ofinterstitial fibrosis (F), the alveoli (A) are lined by flattened epithelial
cells, some ofwhich are ciliated. Methacrylate section, H & E stain, x 1000. Reproduced from Adamson and Bowden (20) with permission.DRUG-INDUCED PULMONARY FIBROSIS
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FIGURE 11. Plots of (bottom) percentage of 3H-thymidine labeled
cells at various times after a single IV injection of bleomycin to
mice (120 mg/kg); (top) pulmonary cell types showing the time
span of increased thymidine incorporation as determined from
differential counts of labeled cells: (END) endothelium; (EP)
epithelial; (INT) interstitial. Reproduced from Adamson and
Bowden (47) with permnission.
not develop. Followingbleomycin treatment, endothelial
repair occurs quicklybut, after aperiod ofepithelial cell
division, a variety of inappropriate, poorly differenti-
ated cell forms are seen. The overall sequence ofcellular
injury and repair reveals that epithelial injury and
regeneration started before the fibroblastic response,
indicating that metaplasia is not the result of an initial
change in the pulmonary interstitium. Rather, the
reverse process may be true; altered and/or delayed
repair ofthe epithelium may have promoted interstitial
fibrosis. This may be the result of severe, acute epithe-
lial injury or repeated exposure to a toxin which by
altering the surface, disturbs the usual epithelial-inter-
stitial cell relationship and promotes fibroblast prolif-
eration. In this way injury to the surface of the lung
may resemble a cutaneous wound where epithelial
destruction is associated with fibroblast proliferation,
which is inhibited subsequently when a normal epithe-
lium is restored. There is evidence to support this
concept from the oxygen poisoning model oflunginjury.
Prolonged exposure to high concentrations of oxygen
resultsindelayed epithelialrepairwithfibrosis, whereas
acute epithelial injury is repaired without fibrosis (30,
34). It is suggested that, in the case of bleomycin, the
epithelial injury and the disordered repair that results
disturbs the usual interrelationships between epithelial
and fibroblastic cells and is a key factor in the develop-
ment of pulmonary fibrosis. In addition to the concept
that surface disruption "switches on" fibroblasts, bleo-
mycin may have a direct effect on these cells since
in tissue culture, it has been shown that bleomycin
stimulates fibroblasts directly to increase collagen
synthesis (35).
It has also been proposed that immunologic mecha-
nisms may play a role in the development ofpulmonary
fibrosis after bleomycin. Although some plasma cells
and lymphocytes are occasionally seen in peribronchial
areas aftermanyintraperitoneal injections, they are not
a prominent or consistent finding. After a large intrave-
nous injection, fibrosis develops in 2 to 4 weeks without
such a cellular infiltrate (20). Recent studies in both
athymic mice (36) and baboons (24) demonstrate that
interstitial lung disease can be produced by bleomycin
without the involvement of cellular immune processes.
MechanismsofInjuryand Repair
If, as suggested above, injury to the alveolar epi-
thelium and its subsequent abnormal repair are crucial
factors in the pathogenesis of bleomycin induced
pulmonary fibrosis, further evidence should be sought
for the role of the drug in epithelial reactivity and
altered differentiation during repair. The toxicity of
bleomycin to cells in division is the basis forits use as an
anti-tumor agent and tissue culture studies have shown
that the drug acts at various stages ofthe cell cycle (a)
by breaking DNA strands (37), (b) by inhibiting the
entry of cells into mitosis (38) and (c) by retarding the
passage of cells through the mitotic cycle (39). Two
hours after administration of 14C-labeled bleomycin,
isotope was detected at the cell membrane and reached
the nuclear membrane by 4 hr; necrotic cells had heavy
cytoplasmic label (40). This is supportive evidence for
the theory that cells contain varying amounts of an
inactive enzyme in the cytoplasm and that cells with low
levels of this enzyme are most susceptible to injury by
bleomycin. It has been shown inmice that squamous cell
carcinomas, readily controlled by bleomycin, possess
less inactivating enzyme than more resistant sarcomas
(14). In a study by Ohnuma, homogenates of various
tissues were incubated with bleomycin and drug inac-
tivation was followed (41). Liver, intestine, spleen,
plasma and kidney all contained more inactivation
enzyme than skin and lung. This is the inverse of drug
retention from in vivo studies of Umezawa et al. (10),
where bleomycin content was highest in lung and skin,
the organs of lowest inactivation enzyme content. In
studies ofthe reaction ofskin to bleomycin, the drugnot
only inhibited the proliferation ofepidermal cells, but it
also altered cellular maturation (42).
Acommonfactorbetween lungand skin appears to be
the extensive covering by epithelial cells, which contain
low levels of detoxifying enzymes to cleave the car-
boxyamide groups of bleomycin. Once across the
cytoplasm, the drugaffects the nucleus where it inserts
between the double helix, causing strand scission (37).
This process is reversible; however, ifthe cell is involved
in replication before DNA is repaired, an abnormal cell
is produced (43), leading to secondary changes in RNA
and protein (44). In vitro experiments have shown that
the differential susceptibility of cells to bleomycin
depends on the phase of the cell cycle (15). Some cells
may be inhibited from entering mitosis, others with
DNA damage during G1 and S phases may replicate
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abnormally. In mouse skin, bleomycin depresses the
number of cells in mitosis, their passage time through
the cycle and inhibits cellular maturation (42). The
effects on epithelial differentiation have been demon-
strated in a clinical study using serial biopsies of
carcinoma ofthe tongue. Bleomycin treatment reduced
cell division and promoted the accumulation of tono-
filaments in tumor cells which later produced keratinic
epithelial pearls, indicative of altered epithelial cell
differentiation (45). These combined results suggest
that, whereas bleomycin may partially inhibit cells from
division, it has also an effect on differentiating post
mitotic epithelial cells.
The present experimental evidence suggests that
bleomycin is selectively retained by the lung where it
damages endothelial and Type I epithelial cells. It is
reasonable to speculate that the drug may also be
incorporated into Type II cells at the same time and its
effects manifested during the critical period ofType II
cellproliferationwhen, insomeinstances, severenuclear
damage to Type II cells was observed (Fig. 8). It seems,
therefore, that the reactivity oftheType II celldepends
upon its phase in the cell cycle. In the restingG. phase,
the cell appeared resistant to bleomycin whereas in the
proliferative andtransformation phases, cellular changes
were observed. As in other epithelial cell systems
described above, the drug may influence the processes
of cellular differentiation in the alveolar epithelium.
This would also explain the exaggerated metaplastic
response observed following multiple injections of
bleomycin in which there is continuing insult to the
actively dividing or recently divided Type II cell
population by newly administered drug.
These theories on the action of bleomycin on differ-
entiating Type II cells and the link between abnormal
repair and fibrosis are based on the premise that
bleomycin is present at the critical period ofrepair. It is
known that the lung is relatively deficient in an enzyme
which detoxifies bleomycin (9,10), and this probably
accounts for the selective retention of the drug in the
lung (46). Following 50 mg/kg IP to mice, bleomycin was
retained for up to 5 days in skin and lung whereas the
drug was rapidly cleared from liver and kidney. To test
the hypothesis that bleomycin is present in the lung
duringthe phases ofdivision and differentiation ofType
II cells, Adamson and Bowden (47) used tritiated
bleomycin to correlate cellular injury and repair with
drug presence in the lung. After a single intravenous
injection, significant levels of bleomycin were present
during the periods of Type I cell necrosis and Type II
cell proliferation. It was suggested that the subsequent
epithelialmetaplasia was due tothecontinuingpresence
of the drug in Type II cells at the critical phase of
mitosis (Fig. 12).
These results were substantiated by experiments in
which biweekly intraperitoneal injections of tritiated
bleomycin were given to mice. When the drug was
administered atthe time ofType II cellproliferation, an
exaggerated epithelial metaplasia was produced and
DP.M.
x 104
IN
LUNG
END.
INJURt
-EP2 PROLIF AND METAPLASIA-'_
EPI -1
INJURY
END.
-REPAIW'
DAYS AFTER ONE I.V. 3H BLEOMYCIN (120mg/kg)
FIGURE 12. Plots of(bottom) mean values for radioactivity (dpm) in
30 mg mouse lung samples at intervals after a single IV injection
of3H-bleomycin (120 mg/kg); (top) time sequence ofcellular events
after the single IV dose of bleomycin.
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30 mg mouse lung samples at intervals after twice weekly IP
injections of 3H-bleomycin (20 mg/kg) for 8 weeks; (top) time
sequences of the cellular events after multiple injections of
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inappropriate cell types described earlier were found
lining alveoli. At this time progressive accumulation of
3H-bleomycin in the lung was observed by scintillation
counting (Fig. 13) and the autoradiographs indicated a
selective concentration ofthe drug in Type II cells (47).
Fromthe sequentialdata onmorphology, DNAsynthesis
in epithelial cells and drug retention, it was concluded
that sufficient bleomycin was present to affect the Type
II cell during its proliferative phase. Division of these
cells occurred, but the processes of cellular differ-
entiation were disturbed sufficiently to produce cell
forms varying from typical bronchial to typical alveolar
epithelium in association with areas of fibrosis. Oc-
casionally a few such epithelial cells have been seen in
"normal" lung shere they have been attributed to a
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developmental abnormalityrelated tothecommonorigin
of all pulmonary epithelium (48). It appears therefore
that the metaplastic cells seen after bleomycin are the
result of drug effects on the synthetic mechanisms of
the differentiating epithelial cells.
The finding of various epithelial cell types overlying
areas of fibrosis suggests that the abnormal differen-
tiationdidnotrestorethenormalepithelial-mesenchymal
control mechanisms that usually limit fibroblastic
activity in the interstitium. The fibrotic reaction with
reactive hyperplasia and metaplasia of alveolar epi-
thelium is not specific to bleomycin toxicity, since
similar responses have been observed clinically in the
various forms of diffuse pulmonary fibrosis or fibrosing
alveolitis (16,49). It is suggested, however, that a
common mechanism may apply in these cases and
involve the reaction ofType II cell as the crucial factor.
Whereas acute injury to endothelium and epithelium
may be rapidly repaired with no fibrosis, continuing
injury with delayed or disturbed regeneration is asso-
ciated with fibroblastic activity (35,50). Type I cells are
particularly vulnerable to injury and, in the steady
state, the TIype II cell with its slow turnoveris generally
considered to be injury resistant. However, in the
regenerative phase the total population of these cells
may turn over in 3 days (30), and Type II cells have now
been demonstrated as susceptible to injury during
division by persisting or newly administered cytotoxic
agents. Thisisofparticularsignificance inchemotherapy
where repeated, frequent administration of drugs such
as bleomycin increases the chance of drug interaction
with TIype II cells dividing in response to previous Type
I cell injury. The therapeutic action of bleomycin is
dependent on its ability to control the division ofrapidly
dividing cells, and it is particularly effective on tumors
of epithelial origin. These facts are consistent with the
present observations of the particular sensitivity of
dividing TIype II epithelial cells to the drug, with the
subsequent development of pulmonary fibrosis during
the time of abnormal epithelial repair.
In conclusion, experimental studies indicate that
diffuse pulmonary fibrosis maybe the result ofageneral
repair mechanism following injury to the alveolar wall.
Many different agents may cause the initial toxic insult
but factors such as the extent of injury, local concen-
tration and retention ofthe toxin, and any repetition of
insult, determine whether or not the air-blood barrier
can be repaired quickly. Focal denuding ofthe epithelial
surface can allow plasma proteins to flow into the
alveolus followed by migration offibroblasts to produce
nodules of intra-alveolar fibrosis. Diffuse interstitial
fibrosis may result from disturbance of the usual
epithelial-mesenchymal cell interrelationships at the
alveolar surface. Any disruption to this control mech-
anism by extensive epithelial necrosis, delayed or
inappropriate cellular repair may be crucial to insti-
gating the fibrotic process in the pulmonary inter-
stitium. The picture of diffuse fibrosis with epithelial
hyperplasia and metaplasia is common enough to
suggest that this proposed mechanism for the action of
bleomycin applies to many toxins that damage the
alveolar wall.
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